Related Experiment Videos
Allogeneic bone marrow transplantation (BMT) for acquired severe aplastic anaemia (SAA) in children
Insights
Pediatric bone marrow transplants for acquired aplastic anemia show improved survival rates, especially with recent transplant years. Early diagnosis and specific immunosuppressants are key factors for better outcomes in children.
Area of Science:
- Pediatric Hematology
- Hematopoietic Stem Cell Transplantation
- Immunosuppression Therapy
Background:
- Acquired aplastic anemia (SAA) is a severe condition in children.
- Bone marrow transplantation (BMT) is a potential curative treatment for SAA.
- Long-term survival data for pediatric BMT in SAA is crucial.
Purpose of the Study:
- To analyze survival outcomes in children with acquired SAA undergoing BMT.
- To identify prognostic factors influencing survival in this pediatric cohort.
- To evaluate the impact of transplant era and procedures on survival.
Main Methods:
- Retrospective analysis of 171 children with acquired SAA undergoing BMT (1970-1988).
- Data collected by the SAA Registry of the European Group for Blood and Marrow Transplantation (EBMT).
- Multivariate Cox regression and univariate analyses were performed.
Main Results:
- Overall 10-year actuarial survival was 63%.
- Transplant year was a significant prognostic factor: 1984-88 (81%) vs 1981-83 (67%) vs 1970-80 (41%) (p=0.02).
- Favorable factors included Cyclosporine A for GVHD prophylaxis, no prior treatment, and <90 days from diagnosis to BMT.
Conclusions:
- Survival rates for pediatric BMT in SAA have significantly improved over time.
- Specific immunosuppressive protocols (Cyclophosphamide + Cyclosporine A) show better results.
- Timely BMT and appropriate GVHD prophylaxis are critical for improved outcomes.
Abstract:
The SAA Registry of the EBMT now contains data on 171 children younger than 15 years of age with acquired SAA and undergoing BMT between 1970 and 1988. The overall actuarial survival is 63% at 10 years. In a multivariate Cox analysis, the year of transplant was the most important prognostic factor with a significant advantage for children grafted in 1984-88 (81%) vs 1981-83 (67%) and 1970-80 (41%) (p = 0.02). Cyclosporine A given for GVHD prophylaxis, no treatment before transplant and an interval less than 90 days from diagnosis to BMT were all favourable variables in univariate analysis. As regard to transplant procedures, the better results were obtained using Cyclophosphamide and Cyclosporine A (78%) followed by Cyclophosphamide plus irradiation plus Cyclosporine A (77%). Sex, etiology and the severity of the aplasia had no impact on survival in both uni and multivariate analysis.